The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $6,351,460 in first-year total cost, median $1,634,230.
Most frequent study sections
- Special Emphasis Panel[ZCA1 TCRB-Q (J1)]4
Most frequent institutions
- BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC.1
- DOSEOPTICS, LLC1
- LEUKO LABS, INC.1
- PRIVO TECHNOLOGIES, LLC1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2024 | Support for Registration Enabling Phase 3 Clinical Trial for Nanotechnology-Based Treatment of Carcinoma in Situ of the Oral Cavity (Stage 0 Oral Cancer)2R44CA281020-07A1 | GOLDBERG, MANIJEH NWEBB, MARCUS | PRIVO TECHNOLOGIES, LLC, MA | $2,084,026 | ZCA1 |
| 2024 | Reducing the incidence of febrile neutropenia in cancer patients treated with chemotherapy with PointCheck: a portable non-invasive neutropenia analyzer2R44CA228920-04 | CASTRO-GONZALEZ, CARLOS | LEUKO LABS, INC., MA | $1,702,979 | ZCA1 |
| 2024 | Biomarker Rich Clinical Trial of an Innovative Antibody Antagonist of TNFR2 in Non-Hodgkin Lymphoma Featuring Cutaneous T Cell Lymphoma (CTCL).2R44CA265510-04 | BROOKS, DAVID G | BOSTON IMMUNE TECHNOLOGIES AND THERAPEUTICS, INC., MA | $1,565,481 | ZCA1 |
| 2024 | DoseRT™ : A Non-Contact Optical Patient and Beam Dosimetry System for Continuous in vivo Radiotherapy Verification2R44CA232879-04A1 | WARE, WILLIAM | DOSEOPTICS, LLC, NH | $998,974 | ZCA1 |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.